

Product Information

SIGMAFAST™ Protease Inhibitor Cocktail Tablets, EDTA-Free

for use in purification of Histidine-tagged proteins

S8830

Product Description

Crude cell extracts contain many endogenous enzymes, such as proteases, which can degrade the proteins present in the sample. The best way to preserve the integrity of the proteins is to add a broad spectrum of protease inhibitors tailored to the sample and task.

The SigmaFAST™ Protease Inhibitor Cocktail Tablet, EDTA-Free is a mixture of protease inhibitors with a broad specificity for the inhibition of serine, cysteine, aspartic, and metalloproteases. The tablets have been formulated to be compatible with sample processing by immobilized metal affinity chromatography (IMAC) such as used for the purification of histidine-tagged (His-tagged) proteins. The tablets contain no strong metal chelators, such as EDTA, which might interfere with IMAC processing. Finally, the tablets contain a unique, proprietary formulation which includes a pepstatin A salt to provide additional protection not normally obtained in a tablet format. The broad protection afforded allows use of these tablets to purify His-tagged proteins and as a general-purpose protease inhibitor cocktail.

Several theses¹ and dissertations²⁻¹⁰ have cited use of product S8830 in their protocols.

Components

Each tablet can be used to prepare 100 mL of 1× protease inhibitor solution, which contains the following inhibitor concentrations:

- AEBSF: 2 mM
- Phosphoramidon: 1 μM
- Bestatin: 130 μM
- E-64: 14 μM
- Leupeptin: 1 μM
- Aprotinin: 0.2 μM
- Pepstatin A: 10 μM

Specific inhibitory properties of the components are:

- AEBSF [4-(2-Aminoethyl)benzenesulfonyl fluoridehydrochloride]: serine proteases, such as trypsin, chymotrypsin, plasmin, kallikrein, and thrombin
- Bestatin hydrochloride: aminopeptidases, such as leucine aminopeptidase and alanyl aminopeptidase¹¹⁻¹⁴
- Leupeptin: serine and cysteine proteases, such as trypsin, plasmin, trypsinogen, urokinase, and kallikrein¹³
- E-64 [*N*-(trans-Epoxy succinyl)-L-leucine 4-guanidinobutylamide]: cysteine proteases, such as calpain, papain, cathepsin B, and cathepsin L¹¹
- Aprotinin: serine protease, such as chymotrypsin, trypsin, and elastase
- Pepstatin A: acid proteases, such as pepsin, renin, and cathepsin D, and many microbial aspartic proteases
- Phosphoramidon disodium salt: thermolysin and collagenase

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

The tablets are stable as supplied for at least 2 years at 2-8 °C. The reconstituted protease inhibitor solution (1× or 10×) is stable for at least 2 weeks at 2-8 °C.

Preparation Instructions

One tablet generates 100 mL of 1× protease inhibitor solution. Each tablet can be reconstituted in either water or extraction/lysis buffer.

A tablet may also be used to prepare a 10× protease inhibitor solution, which can be diluted as needed. Concentrations greater than 1× may appear slightly hazy. This will not affect the performance of the protease inhibitors. Mix the 10× protease inhibitor solution (15 minutes) until uniformly suspended, and then dilute as appropriate.

Procedure

- One tablet is recommended for the inhibition of the proteases present in a maximum of 20 g of cell mass in 100 mL of extract.
- The inhibitor mixture may be dissolved directly in the extraction reagent or added from the 10× protease inhibitor solution immediately following extraction.
- Since not all organisms contain the same amounts of endogenous proteases, it may sometimes be necessary to increase the concentration of inhibitors.

References

1. McLaughlin, Dylan, "Characterizing effects of sumoylation on Thymine-DNA Glycosylase base excision repair activity *in vivo*". Johns Hopkins University, M.S. thesis, p. 6 (2014).
2. Gagnon, Michael Dore, "Engineering lipases and solvents for trans/-esterification of used vegetable oils". University of New Hampshire, Ph.D. dissertation, p. 72 (2013).
3. Alghamri, Mahmoud Soliman Salem, "Novel therapeutic approach for regulating the susceptibility of epitheliato adenovirus infection". Wright State University, Ph.D. dissertation, p. 46 (2016).
4. Fütterer, Jane Wong, "Characterisation of a novel protein, ANKRD18A, implicated in a severe form of thrombocytopenia". University of Birmingham, Ph.D. dissertation, p. 105 (2016).
5. Trotman, Jackson B., "New Insights into the Biochemistry and Cell Biology of RNA Recapping". The Ohio State University, Ph.D. dissertation, p. 129 (2018).
6. Arsiwala, Ammar, "Engineering protein antigens to refocus the immune response". Georgia Institute of Technology, Ph.D. dissertation, p. 13 (2019).
7. Ozdemir, Ahmet Y., "Biochemical Studies of DNA Polymerase Theta". Temple University, Ph.D. dissertation, p. 36 (2019).

8. Aguirre, Ana Lucia Cabello, "The *Brucella* Effector Grhg1 Reprograms the Host *N*-Glycome to Sustain Infection". Texas A&M University, Ph.D. dissertation, p. 111 (2020).
9. Vranic, Marija, "3D Structure of the Biomarker Hepcidin-25 in its Native State". Universität Potsdam, Dr. rer. nat. dissertation, p. 94 (2020).
10. Ismail, Sherif, "Identification of the Primordial Pre-60S Subunit and How it Emerges from the 90S Pre-ribosome". Ruperto Carola University Heidelberg, Dr. rer. nat. dissertation, p. 67 (2021).
11. Aoyagi, T., and Umezawa, H., *Acta Biol. Med. Ger.*, **40(10-11)**, 1523-1529 (1981).
12. Umezawa, H., *Ann. Rev. Microbiol.*, **36**, 75-99 (1982).
13. Mumford, R.A. *et al.*, *Biochem. Biophys. Res. Comm.*, **103(2)**, 565-572 (1981).
14. Aoyagi, T. *et al.*, *Biochem. Int.*, **9(4)**, 405-411 (1984).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Standard Warranty

The applicable warranty for the products listed in this publication may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

S8830dat Rev 05/22 JGD,RMT,GCY,MAM

**MILLIPORE
SIGMA**